Literature DB >> 25199412

Triple-marker PCR assay of sentinel lymph node as a prognostic factor in melanoma.

T Ito1, M Wada, K Nagae, M Nakano-Nakamura, T Nakahara, A Hagihara, M Furue, H Uchi.   

Abstract

BACKGROUND: Metastasis of sentinel lymph node (SLN) is generally evaluated on histopathological examination and controversy still exists over the usefulness of PCR assay of SLN.
OBJECTIVE: To investigate the prognostic value of triple-marker PCR assay of SLN.
METHODS: A total of 165 patients with primary cutaneous melanoma who underwent SLN biopsy were included. Clinical and histopathological data were retrieved from each patient's file and triple-marker PCR assay (tyrosinase, GP-100 and MART-1) was performed on the SLN as well as routine histopathological evaluation. PCR positivity was defined as the expression of all three PCR markers. To evaluate melanoma-specific survival (MSS) and disease-free survival (DFS), we used the Kaplan-Meier method and the log-rank test. Multivariate analyses using the Cox proportional hazards regression model were also performed.
RESULTS: Sentinel lymph nodes were identified in all 165 patients: 61 patients (37.0%) were male and 104 (63.0%) were female, with a mean age of 60.2 years. Of the 165 melanomas, 81 (49.1%) were acral lentiginous melanomas. Compared with the patients with PCR positivity (1-2 markers) or PCR negativity, patients with PCR positivity (3 markers) had significantly poor MSS (5-year survival rate, 58.7% vs. 84.4%; P < 0.0001) and DFS (5-year survival rate, 25.0% vs. 83.9%; P < 0.0001), with median follow-up of 42 months for MSS and 38 months for DFS. These survival rates of patients with PCR positivity (3 markers) were lower than those of patients with histopathologically positive SLN. In multivariate analysis, PCR positivity (3 markers) was an independent prognostic factor for both MSS (hazard ratio [HR], 2.81; 95% confidence interval [CI], 1.07-7.33; P = 0.035) and DFS (HR, 2.48; 95% CI, 1.08-5.69; P = 0.032).
CONCLUSIONS: The expression of three PCR markers was a significant prognostic factor for both MSS and DFS and might be closely correlated to a dismal prognosis.
© 2014 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25199412     DOI: 10.1111/jdv.12722

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  3 in total

1.  Cutaneous angiosarcoma of the head and face: a single-center analysis of treatment outcomes in 43 patients in Japan.

Authors:  Takamichi Ito; Hiroshi Uchi; Takeshi Nakahara; Gaku Tsuji; Yoshinao Oda; Akihito Hagihara; Masutaka Furue
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-25       Impact factor: 4.553

2.  Intra- and Inter-Tumor BRAF Heterogeneity in Acral Melanoma: An Immunohistochemical Analysis.

Authors:  Takamichi Ito; Yumiko Kaku-Ito; Maho Murata; Toshio Ichiki; Yuki Kuma; Yuka Tanaka; Taketoshi Ide; Fumitaka Ohno; Maiko Wada-Ohno; Yuichi Yamada; Yoshinao Oda; Masutaka Furue
Journal:  Int J Mol Sci       Date:  2019-12-08       Impact factor: 5.923

3.  Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival.

Authors:  Takamichi Ito; Yumiko Kaku-Ito; Maho Murata; Kazuhisa Furue; Che-Hung Shen; Yoshinao Oda; Masutaka Furue
Journal:  J Clin Med       Date:  2020-03-04       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.